Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) plus pemetrexed/cisplatin (PEM/CIS) vs placebo (P) plus PEM/CIS in chemo-naive patients (pts) with malignant pleural mesothelioma (MPM)

S. Novello, A. K. Nowak, F. Grosso, N. Steele, S. Popat, L. Greillier, T. John, N. B. Leighl, M. Reck, N. Pavlakis, J. B. Sorensen, D. Planchard, G. L. Ceresoli, B. Hughes, J. Mazieres, M. A. Socinski, U. von Wangenheim, J. Barrueco, N. Morsli, G. Scagliotti

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

2 Citations (Web of Science)
Original languageEnglish
Number of pages2
JournalAnnals of Oncology
Publication statusPublished - Sept 2017
Event42nd European-Society-for-Medical-Oncology Congress (ESMO) - Madrid, Spain
Duration: 8 Sept 201712 Sept 2017

Cite this